Dr med. Vladan Rajić
LEKAR SPECIJALISTA PEDIJATRIJEObrazovanje:
Medicinski fakultet, Univerzitet u Beogradu
Doktorat, Medicinski fakultet, Univerzitet u Ljubljani
Radno iskustvo:
1994-2004 Lekar specijalista pedijatrije, Služba za endokrinologiju, Intenzivna terapija i nega, Institut za majku i dete Dr V. Čupić, Beograd
2004-2023 Lekar specijalista pedijatrije - hematoonkolog, Služba ze hematologiju, onkologiju i presađivanje matičnih ćelija hematopoeze, Univerzitetski klinički centar Ljubljana, Pedijatrijska klinika, Ljubljana
2006- Asistent, Katedra za pedijatriju, Medicinski fakultet, Ljubljana
2021- Docent, Katedra za pedijatriju, Medicinski fakultet, Ljubljana
2023-2024 Lekar specijalista pedijatrije - hematoonkolog, Služba ze hematologiju, UDK Tiršova, Beograd
2024- Lekar specijalista pedijatrije - hematoonkolog, Dom zdravlja MediGroup Narodnih heroja, Beograd
Oblast rada:
Pedijatrija - hematologija i onkologija
Presađivanje matičnih ćelija hematopoeze
Upotreba CAR-T ćelijskog produkta za lečenje rezistentnih ALL
Članstva:
2005- Member of the European society for paediatric oncology
2005- The European society for blood and marrow transplantation
Stručni tekstovi i reference:
Doktorat na Medicinskom fakultetu Univerziteta u Ljubljani, doktorska teza: The impact of polymorphism in GRIA1 gene to allergic reactions to the L-asparaginase.
2009 Rajić V, Aplanc R, Debeljak M, Velenšek Prestor V, Karas-Kuželički N, Mlinarič- Raščan I, Jazbec J. Influence of the polymorphism in candidate genes on late cardiac damage in patient treated due to acute leukaemia in childhood. Leukemia & Lymphoma 2009; 50(10): 1693 – 1698.
2014 Rajić V, Benedik Dolničar M, Jazbec J. (2014). Haematology. In C. Kržišnik (ed.), Textbook of Pediatrics (409-425). Ljubljana: DZS, založništvo in trgovina, d.d.
2015 Rajić V, Debeljak M, Goričar K, Jazbec J. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL. Leuk Lymphoma 2015 :1-6.
2022 Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL- C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022; 23:125-137. doi: 10.1016/S1470-2045(21)00470-8.
2023 Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol. 2023; 24:252-261. doi: 10.1016/S1470-2045(23)00019-0.
